Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database

Lung, Respiratory and Thoracic Cancer

Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy

J Thorac Oncol

Wiesweg M, Alaffas A, Rasokat A, Saalfeld FC, Rost M, Assmann C, Herster F, Hilbrandt M, Griesinger F, Kron A, Roeper J, Glanemann F, Kropf-Sanchen C, Reck M, Kulhavy J, Stenzinger A, Wolf J, Sebastian M, Schuler M, Wermke M, Frost N, Kopp HG, Christopoulos P, Scheffler M

doi: 10.1016/j.jtho.2025.04.016

Skin Cancer

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Lancet Oncol

Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M, Chiarion-Sileni V, Smylie M, Manikhas GM, Dummer R, Wiggins JM, Ali S, Adnaik SB, Tan M, Dajee M, Polsky D

doi: 10.1016/S1470-2045(25)00139-1

Lung, Respiratory and Thoracic Cancer

Treatment outcome of NSCLC patients with BRAF(non-V600E) mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany

ESMO Open

Kropf-Sanchen C, Rasokat A, Christopoulos P, Wenzel C, Wehler T, Rost M, Kulhavy J, Reinmuth N, Schulz C, Scheffler M, Wolf J, Büttner R, Merkelbach-Bruse S, Thomas M, Stenzinger A, Schütz M, Bräuninger A, Demes M, Hummel HD, Pfarr N, Gaisa NT, Rawluk J, Berezucki E, Lutz KT, Galda S, Jacobi H, Collienne M, Janning M, Brummer T, Loges S, nNGM Lung Cancer

doi: 10.1016/j.esmoop.2025.105124

Skin Cancer

First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG

Eur J Cancer

Reinhard S, Utikal JS, Zaremba A, Lodde G, von Wasielewski I, Klespe KC, Meier F, Haferkamp S, Kähler KC, Herbst R, Gebhardt C, Sindrilaru A, Dippel E, Angela Y, Mohr P, Pfoehler C, Forschner A, Kaatz M, Schell B, Gesierich A, Loquai C, Hassel JC, Ulrich J, Meiss F, Schley G, Heinzerling LM, Sachse M, Welzel J, Weishaupt C, Sunderkötter C, Michl C, Lindhof HH, Kreuter A, Heppt MV, Wenk S, Mauch C, Berking C, Nedwed AS, Gutzmer R, Leiter U, Schadendorf D, Ugurel S, Weichenthal M, Haist M, Fleischer MI, Lang B, Grabbe S, Stege H

doi: 10.1016/j.ejca.2025.115356

Skin Cancer

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Eur J Cancer

Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C

doi: 10.1016/j.ejca.2024.115160

Skin Cancer

Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients

J Clin Oncol

Lodde GC, Hassel JC, von Wasielewski I, Meier F, Mohr P, Kähler K, Hauschild A, Glutsch V, Stege H, Berking C, Hüning S, Huynh J, Gutzmer R, Reinhardt L, Schilling B, Loquai C, Erdmann M, Stang A, Kowall B, Galetzka W, Roesch A, Tilkorn D, Ugurel S, Zimmer L, Schadendorf D, Forschner A, Livingstone E

doi: 10.1200/JCO-24-02776

Lung, Respiratory and Thoracic Cancer

Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study

Clin Lung Cancer

Atlagh L, Toublanc AC, Roch B, Marinello A, Ruuth-Praz J, Cousin S, Chouaid C, Basset C, Evrard S, Duruisseaux M, Girard N, Durand K, Mazières J, Brindel A

doi: 10.1016/j.cllc.2025.06.005

Skin Cancer

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

Ann Oncol

Martín-Lluesma S, Dafni U, Vervita K, Karlis D, Dimopoulou G, Tsourti Z, Villacampa G, Galvao V, Lostes J, Muñoz-Couselo E, Rotxés M, Villalobos X, Muñoz S, Haanen JBAG, Svane IM, Piulats JM, Martin-Liberal J, Gros A, Coukos G, Garralda E

doi: 10.1016/j.annonc.2025.04.001

Multiple Myeloma (MM)

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Blood

Merz M, Gagelmann N, Smaili S, Flossdorf S, Sauer S, Scheid C, von Tresckow B, Wulf GG, Weisel KC, Blau I, Engelhardt M, Wäsch R, Schub N, Teipel R, Hecker JS, Waldschmidt JM, Besemer B, Baermann BN, Call S, Hansmann L, Ayuk FA, Raab MS, Einsele H, Platzbecker U, Kröger N

doi: 10.1182/blood.2025028330

Related content

Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Treatment outcome of NSCLC patients with BRAF(non-V600E) mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany

First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients

Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST